Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.10.002Source: DataRank Database

Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program is a research paper published in Clinical Genitourinary Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (37 grants)OA: greenTopics (19)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Sarah K. Holt ORCID,Ali Raza Khaki ORCID,Rishi Sekar ORCID,Adam J. Gadzinski ORCID,Yaw A. Nyame ORCID

Live enrichment

PubMed:33160889 PMC:PMC8044249

National Cancer Institute

Grant: T32CA009515

Intramural VA

Grant: VA999999

Clovis Oncology

Immunomedics

Janssen Oncology

ESSA

MDxHealth

Color Foundation

Hoffman-La Roche

Merck

Oncogenex

Sanofi

Taiho

Ventana Medical Systems

Bavarian Nordic

Debiopharm

GenomeDx

GlaxoSmithKline

Madison Vaccines

QED Therapeutics

Bayer

Dendreon

Ferring Pharmaceuticals

Genentech

Astellas Medivation

Ferring

INOVIO Pharmaceuticals

Pfizer

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Kure It Cancer Research

Mirati Therapeutics

Seattle Genetics

Daiichi-Sankyo

Janssen

Zenith

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8044249

publisherhttps://api.elsevier.com/content/article/PII:S1558767320302299?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1558767320302299?httpAccept=text/plain

MeSH Terms

HumansCarcinoma, Transitional CellNeoplasm StagingNeoadjuvant TherapyCystectomyRetrospective StudiesAgedInfant, NewbornMedicareUnited StatesFemaleMaleUrinary Bladder NeoplasmsTertiary Care Centers

Keywords

CystectomyNeoadjuvant TherapyUrinary Bladder NeoplasmsSeer ProgramPathologic Response

Additional file 1 of The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

10.6084/m9.figshare.26617675.v1figshare

Additional file 1 of The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy

10.6084/m9.figshare.26617675figshare